Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies

被引:0
作者
Tyler Ellis Smith
Ilya Kister
机构
[1] NYU School of Medicine,Department of Neurology, NYU
来源
Current Neurology and Neuroscience Reports | 2021年 / 21卷
关键词
Multiple sclerosis; Disease-modifying therapy; Treatment; Infections; Risk mitigation; Adverse events;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 807 条
[11]  
Luzzio C(2009)Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis b undergoing anticancer therapy with or without rituximab J Clin Oncol 27 605-611
[12]  
Myers L(2019)Reactivation of hepatitis b virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis Open Forum Infect Dis 6 ofy356-358
[13]  
Panitch H(2020)Hepatitis B Virus Reactivation Potentiated by Biologics Infect Dis Clin N Am 34 341-1599
[14]  
Preiningerova J(2018)Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Hepatology. 67 1560-31
[15]  
Pruitt A(2018)Prevention of hepatitis B virus infection in the united states: recommendations of the Advisory Committee on Immunization Practices MMWR Recomm Rep 67 1-887
[16]  
Rose J(2020)Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis J Formos Med Assoc 119 886-258
[17]  
Rus H(2015)Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis Neurol Neuroimmunol Neuroinflamm 2 e72-381
[18]  
Wolinsky J(2005)Hepatitis B virus reactivation and alemtuzumab therapy Eur J Haematol 74 254-1602
[19]  
Ancau M(1996)Varicella-zoster virus Clin Microbiol Rev 9 361-339
[20]  
Berthele A(2015)A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation J Gen Virol 96 1581-39